Marktstudien » Technologie / Medien » Informationstechnologie IT » Informationstechnologie IT allgemein u. sonstige »
|
European and US Digital TV, 2008 (Strategic Focus)
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
•Track key sector trends for digital television platforms. •Obtain subscriber data on key service operators. 41 pages | |||||||||||
| Inhalt der Studie: |
The broadcast sector is evolving as consumers expect more from their TV offerings and on-demand services transform the method consumers obtain content. As service operators compete in an crowded marke.....
The broadcast sector is evolving as consumers expect more from their TV offerings and on-demand services transform the method consumers obtain content. As service operators compete in an crowded marketplace, there is rising pressure on reducing churn to alternative networks. This report provides national DTV subscriber market sizes as well as forecasts for potential platform growth until 2012. Report Highlights Highlights platform adoption split by digital cable, satellite, digital terrestrial television (DTT) and Internet protocol television (IPTV). •Subscriber numbers for each service operator split by platform and national market. DTV adoption is expected to illustrate strong growth over the next 2-3 years as consumers demand enhanced service functionality including on-demand entertainment and bundled communications offerings. A key driver in the transition to DTV services is the switch off of analog transmission in the US and Western Europe. With the US switch off (ASO) date mandated for February 17th 2009 and most Western European countries switching off transmission before the European 2012 deadline, the next 2-3 years will see significant increases in DTT consumers. [Studien Infos ausblenden] |
|||||||||||
|
CHAPTER 1 EXECUTIVE SUMMARY 3 Strategic scoping and focus 3 Datamonitor insight into the targeted therapy cancer brands market 4 Related reports 5 Upcoming reports 5 CHAPTER 2 MARKET DEFINITION 19 Definition of the cancer market by ATC class 19 Molecular targeted therapies 20 L1X3 – Antineoplastic monoclonal antibodies 20 L1X9 – All other antineoplastics 20 CHAPTER 3 MARKET OVERVIEW AND FORECASTS 21 Seven major markets 21 Current market assessment 21 Sales by class 21 Sales by brand 23 Sales by country 26 Future market assessment 28 Sales by class 28 Sales by brand 30 Sales by country 35 Opportunities and threats 39 US 40 Current market assessment 40 Sales by class 40 Sales by brand 42 Future market assessment 43 Sales by class 43 Sales by brand 46 Japan 49 Current market assessment 49 Sales by class 49 Sales by brand 51 Future market assessment 52 Sales by class 52 Sales by brand 55 5EU 58 Current market assessment 58 Sales by class 58 Sales by brand 60 Future market assessment 61 Sales by class 61 Sales by brand 64 France 67 Current market assessment 67 Sales by class 67 Sales by brand 69 Future market assessment 70 Sales by class 70 Sales by brand 73 Germany 76 Current market assessment 76 Sales by class 76 Sales by brand 78 Future market assessment 79 Sales by class 79 Sales by brand 82 Italy 85 Current market assessment 85 Sales by class 85 Sales by brand 87 Future market assessment 88 Sales by class 88 Sales by brand 91 Spain 94 Current market assessment 94 Sales by class 94 Sales by brand 96 Future market assessment 97 Sales by class 97 Sales by brand 100 UK 103 Current market assessment 103 Sales by class 103 Sales by brand 105 Future market assessment 106 Sales by class 106 Sales by brand 109 Rest of World snapshot 112 Current market assessment 112 Global monoclonal antibody brand market 114 Global small molecule brand market 116 CHAPTER 4 BRAND DYNAMICS 118 Brand analysis by class 118 Seven major markets 119 Analysis of current market 119 Analysis of future market 120 US 123 Analysis of current market 123 Analysis of future market 125 Japan 127 Analysis of current market 127 Analysis of future market 129 5EU 131 Analysis of current market 131 Analysis of future market 133 France 135 Analysis of current market 135 Analysis of future market 137 Germany 139 Analysis of current market 139 Analysis of future market 141 Italy 143 Analysis of current market 143 Analysis of future market 145 Spain 147 Analysis of current market 147 Analysis of future market 149 UK 151 Analysis of current market 151 Analysis of future market 153 Brand analysis by approval date 155 Since 2005, 10 new targeted therapies have reached the market 155 Brand analysis by indication 156 Solid tumors versus hematological malignancies 156 Targeted therapy cancer brands approved for solid tumors had the highest market share and showed the largest growth in 2007 156 Targeted therapy cancer brands approved for solid tumors will gain even more market share by 2017 157 Analysis of brand by number of approved indications 158 Avastin is the leading targeted therapy cancer brand in terms of the number of approved indications 158 Analysis of indication by number of approved targeted therapies 161 Non-Hodgkin’s lymphoma is the indication with the most approved targeted therapy cancer brands 161 Brand analysis by mode of administration 163 Intravenously administered targeted therapy cancer brands have the greatest market share 163 Brand analysis by company 165 23 different companies are involved in the marketing of targeted therapy cancer brands in the seven major markets 165 Co-marketed targeted therapy cancer brands have the largest market share in 2007 167 Brand analysis by event 168 Avastin will experience the greatest number of forecast events across the seven major markets 168 CHAPTER 5 BRAND PROFILES AND FORECASTS 170 Avastin 170 Brand profile 170 Brand forecast events 172 Brand forecast to 2017 173 Avastin set to become the biggest-selling targeted therapy cancer brand in the seven major markets in 2009 174 Bexxar 175 Brand profile 175 Brand forecast events 176 Brand forecast to 2017 176 Campath 177 Brand profile 177 Brand forecast events 178 Brand forecast to 2017 179 Erbitux 180 Brand profile 180 Brand forecast events 181 Brand forecast to 2017 182 Erbitux seven major market sales passed $1 billion in 2007 and are set for modest growth through line extensions and new approvals 182 Gleevec 184 Brand profile 184 Brand forecast events 185 Brand forecast to 2017 186 Patent expiries across the seven major markets will curb long-term growth of Gleevec sales 186 Herceptin 188 Brand profile 188 Brand forecast events 189 Brand forecast to 2017 190 Herceptin well placed to maintain strong performance in breast cancer market 190 Iressa 192 Brand profile 192 Brand forecast events 193 Brand forecast to 2017 194 Iressa’s declining sales could experience a turnaround following new Phase III lung cancer trial 194 Mylotarg 196 Brand profile 196 Brand forecast events 197 Brand forecast to 2017 197 Nexavar 198 Brand profile 198 Brand forecast events 199 Brand forecast to 2017 200 Liver cancer approval will help Nexavar to make up for disappointing performance in RCC market 200 Ontak 202 Brand profile 202 Brand forecast events 203 Brand forecast to 2017 203 Revlimid 204 Brand profile 204 Brand forecast events 205 Brand forecast to 2017 206 First-line multiple myeloma approval will allow Revlimid to reach sales of $1 billion in the seven major markets by 2015 206 Rituxan 208 Brand profile 208 Brand forecast events 209 Brand forecast to 2017 210 Rituxan was the biggest-selling targeted therapy cancer brand in 2007 210 Sprycel 212 Brand profile 212 Brand forecast events 213 Brand forecast to 2017 214 Generic imatinib and competition from Tasigna will limit Sprycel’s uptake in first-line CML 214 Sutent 215 Brand profile 215 Brand forecast events 216 Brand forecast to 2017 217 Indication expansion will enable Sutent to become the leading small molecule targeted therapy cancer brand in 2017 217 Tarceva 219 Brand profile 219 Brand forecast events 220 Brand forecast to 2017 221 Additional lung cancer approvals will help drive growth of Tarceva sales 221 Targretin 223 Brand profile 223 Brand forecast events 224 Brand forecast to 2017 225 Tasigna 226 Brand profile 226 Brand forecast events 227 Brand forecast to 2017 228 Tasigna is well-positioned to compensate for Gleevec patent expiry 228 Thalomid 230 Brand profile 230 Brand forecast events 231 Brand forecast to 2017 232 Torisel 233 Brand profile 233 Brand forecast events 234 Brand forecast to 2017 235 Tykerb 236 Brand profile 236 Brand forecast events 237 Brand forecast to 2017 238 Breast cancer line extensions will push Tykerb sales beyond $1.4 billion in the seven major markets by 2017 238 Vectibix 240 Brand profile 240 Brand forecast events 241 Brand forecast to 2017 242 Vectibix is set to lag behind Erbitux and Avastin in the colorectal cancer market 242 Velcade 244 Brand profile 244 Brand forecast events 245 Brand forecast to 2017 246 Velcade seven major market sales will reach $1 billion by 2010 following approval for first-line multiple myeloma 246 Zevalin 248 Brand profile 248 Brand forecast events 249 Brand forecast to 2017 250 Zolinza 251 Brand profile 251 Brand forecast events 252 Brand forecast to 2017 253 APPENDIX A – MARKET ASSUMPTIONS 254 Country-specific assumptions and events 254 Effect of Medicare Modernization Act in the US 254 Biennial price cuts in Japan 254 Generic erosion assumptions 254 Data definitions, limitations and assumptions 255 Standard units 255 Japanese market data 255 Derivation of sales forecasts and pricing trends 255 Forecasts 256 Forecast methodology 256 APPENDIX B 257 Bibliography 257 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 1: Digital television adoption in Western Europe and the US by platform 2007 – 2012e 8 Table 2: Digital television adoption in Austria by platform, 2007 – 2012e 9 Table 3: Digital television adoption in Austria by company, 2007 – 2012e 10 Table 4: Digital television adoption in Austria households data, 2007 – 2012e 10 Table 5: Digital television adoption in Belgium by platform, 2007 – 2012e 11 Table 6: Digital television adoption in Belgium details by company, 2007 – 2012e 12 Table 7: Digital television adoption in Belgium details hosuehold data, 2007 – 2012e 12 Table 8: Digital television adoption in Denmark by platform, 2007 – 2012e 13 Table 9: Digital television adoption in Denmark by company, 2007 – 2012e 14 Table 10: Digital television adoption in Denmark households data, 2007 – 2012e 14 Table 11: Digital television adoption in Finland by platform, 2007 – 2012e 15 Table 12: Digital television adoption in Finland by company, 2007 – 2012e 16 Table 13: Digital television adoption in Finland households data, 2007 – 2012e 16 Table 14: Digital television adoption in France by platform, 2007 – 2012e 17 Table 15: Digital television adoption in France by company, 2007 – 2012e 18 Table 16: Digital television adoption in France households data, 2007 – 2012e 18 Table 17: Digital television adoption in Germany by platform, 2007 – 2012e 19 Table 18: Digital television adoption in Germany by company, 2007 – 2012e 20 Table 19: Digital television adoption in Germany households data, 2007 – 2012e 20 Table 20: Digital television adoption in Italy by platform, 2007 – 2012e 21 Table 21: Digital television adoption in Italy by platform, 2007 – 2012e 22 Table 22: Digital television adoption in Italy households data, 2007 – 2012e 22 Table 23: Digital television adoption in the Netherlands by platform, 2007 – 2012e 23 Table 24: Digital television adoption in the Netherlands by company, 2007 – 2012e 24 Table 25: Digital television adoption in the Netherlands households data, 2007 – 2012e 24 Table 26: Digital television adoption in Norway by platform, 2007 – 2012e 25 Table 27: Digital television adoption in Norway by company, 2007 – 2012e 26 Table 28: Digital television adoption in Norway households data, 2007 – 2012e 26 Table 29: Digital television adoption in Portugal by platform, 2007 – 2012e 27 Table 30: Digital television adoption in Portugal by company, 2007 – 2012e 28 Table 31: Digital television adoption in Portugal households data, 2007 – 2012e 28 Table 32: Digital television adoption in Spain by platform, 2007 – 2012e 29 Table 33: Digital television adoption in Spain by company, 2007 – 2012e 30 Table 34: Digital television adoption in Spain households data, 2007 – 2012e 30 Table 35: Digital television adoption in Sweden by platform, 2007 – 2012e 31 Table 36: Digital television adoption in Sweden by company, 2007 – 2012e 32 Table 37: Digital television adoption in Sweden households data, 2007 – 2012e 32 Table 38: Digital television adoption in Switzerland by platform, 2007 – 2012e 33 Table 39: Digital television adoption in Switzerland by company, 2007 – 2012e 34 Table 40: Digital television adoption in Switzerland household data, 2007 – 2012e 34 Table 41: Digital television adoption in the United Kingdom by platform, 2007 – 2012e 35 Table 42: Digital television adoption in the United Kingdom by company, 2007 – 2012e 36 Table 43: Digital television adoption in the United Kingdom household data, 2007 – 2012e 36 Table 44: Digital television adoption in the US by platform, 2007 – 2012e 37 Table 45: Digital television adoption in the US by company, 2007 – 2012e 38 Table 46: Digital television adoption in the US household d ata, 2007 – 2012e 38 Table 47: Digital television adoption in Western Europe by platform, 2007 – 2012e 39 Figure 1: Digital television adoption in Western Europe and the US, 2007 – 2012e 8 Figure 2: Digital television adoption in Austria, 2007 – 2012e 9 Figure 3: Digital television adoption in Belgium, 2007 – 2012e 11 Figure 4: Digital television adoption in Denmark, 2007 – 2012e 13 Figure 5: Digital television adoption in Finland, 2007 – 2012e 15 Figure 6: Digital television adoption in France, 2007 – 2012e 17 Figure 7: Digital television adoption in Germany, 2007 – 2012e 19 Figure 8: Digital television adoption in Italy, 2007 – 2012e 21 Figure 9: Digital television adoption in the Netherlands, 2007 – 2012e 23 Figure 10: Digital television adoption in Norway, 2007 – 2012e 25 Figure 11: Digital television adoption in Portugal, 2007 – 2012e 27 Figure 12: Digital television adoption in Spain, 2007 – 2012e 29 Figure 13: Digital television adoption in Sweden, 2007 – 2012e 31 Figure 14: Digital television adoption in Switzerland, 2007 – 2012e 33 Figure 15: Digital television adoption in the United Kingdom, 2007 – 2012e 35 Figure 16: Digital television adoption in the US, 2007 – 2012e 37 Figure 17: Digital television adoption in Western Europe, 2007 – 2012e 3 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
